Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel. Show more
Building 7, Tel Aviv-Yafo, 6158002, Israel
Start AI Chat
Market Cap
9.233M
52 Wk Range
$1.40 - $7.04
Previous Close
$1.50
Open
$1.54
Volume
28,003
Day Range
$1.49 - $1.60
Enterprise Value
4.651M
Cash
10.06M
Avg Qtr Burn
N/A
Insider Ownership
13.45%
Institutional Own.
10.57%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nebokitug Details Primary Sclerosing Cholangitis | Phase 2 Update |